title: Paclitaxel-induced diffuse cutaneous sclerosis: a case with associated esophageal dysmotility, Raynaud's phenomenon, and myositis.
authors.affiliation: Intern, O'Bleness Memorial Hospital/OUHCOM, Athens, OH, USA.
authors.forename: Richard R
authors.initials: RR
authors.lastname: Winkelmann
authors.affiliation: Department of Dermatology, Mayo Clinic, Scottsdale, AZ, USA.
authors.forename: James A
authors.initials: JA
authors.lastname: Yiannias
authors.affiliation: Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ, USA.
authors.forename: David J
authors.initials: DJ
authors.lastname: DiCaudo
authors.affiliation: Department of Dermatology, The Ohio State University, Wexner Medical Center, Columbus, OH, USA.
authors.forename: Shannon C
authors.initials: SC
authors.lastname: Trotter
authors.affiliation: Department of Rheumatology, University of Cincinnati, Cincinnati, OH, USA.
authors.forename: Yolanda
authors.initials: Y
authors.lastname: Farhey
authors.affiliation: Department of Rheumatology, Mayo Clinic, Scottsdale, AZ, USA.
authors.forename: W Leroy
authors.initials: WL
authors.lastname: Griffing
authors.affiliation: Intern, University Hospitals Richmond Medical Center, Richmond, OH, USA.
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Martorano
authors.affiliation: Oncology Hematology Care, Cincinnati, OH, USA.
authors.forename: John C
authors.initials: JC
authors.lastname: Winkelmann
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000628:therapy*; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols; D001707:Biopsy, Needle; D016190:Carboplatin / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant; D004359:Drug Therapy, Combination; D015154:Esophageal Motility Disorders / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009220:Myositis / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology; D009361:Neoplasm Invasiveness / Q000473:pathology; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000473:pathology / Q000628:therapy*; D010052:Ovariectomy / Q000379:methods; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects*; D011379:Prognosis; D011928:Raynaud Disease / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology; D018570:Risk Assessment; D012595:Scleroderma, Systemic / Q000139:chemically induced* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D016190:Carboplatin; D017239:Paclitaxel